Teleflex Incorporated (TFX) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 29 analysts11.5% Below Target
TFX trades 11.5% below Wall Street's consensus target of $144.67.
Current Price$129.75
Average Target$144.67
Target
Current
Low$116.00
Median$148.50
High$160.00
Analyst Target Range
Forward P/E19.4x
(Fair)
PEG Ratio—
Implied Growth+129.4%
(High Growth)
Analyst Spread30.4%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes TFX achieves its forward estimates and maintains a stable P/E multiple of 19.4x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
TFX Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Teleflex Incorporated (TFX) has a Wall Street consensus price target of $144.67, based on estimates from 29 covering analysts. With the stock currently trading at $129.75, this represents a potential upside of +11.5%. The company has a market capitalization of $5.74B.
Analyst price targets range from a low of $116.00 to a high of $160.00, representing a 30% spread in expectations. The median target of $148.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TFX trades at a trailing P/E of -6.4x and forward P/E of 19.4x. Analysts expect EPS to grow +129.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+39.6%
Industry Consensus
Avg Forward P/E
143.9x
(High Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICUSeaStar Medical Holding Corporation | $199M | $5.07 | $8.00 | +57.8% | Buy | — | 1 |
 UTMDUtah Medical Products, Inc. | $221M | $69.33 | — | — | — | 11.0x | — |
 ATRCAtriCure, Inc. | $1.7B | $32.80 | $51.33 | +56.5% | Buy | 926.6x | 19 |
 NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
 ANGOAngioDynamics, Inc. | $540M | $13.07 | $16.50 | +26.2% | Hold | — | 11 |
 MMSIMerit Medical Systems, Inc. | $4.3B | $72.14 | $94.20 | +30.6% | Buy | 17.7x | 14 |
 BDXBecton, Dickinson and Company | $56.6B | $156.30 | $174.81 | +11.8% | Hold | 12.4x | 34 |
 BAXBaxter International Inc. | $11.8B | $22.86 | $20.71 | -9.4% | Hold | 11.9x | 36 |
 MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
 BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
TFX — Frequently Asked Questions
Quick answers to the most common questions about buying TFX stock.
What is the TFX stock price target for 2026?
Teleflex Incorporated (TFX) has a consensus 12-month price target of $144.67, implying 11.5% upside from $129.75. The 29 analysts covering TFX see moderate appreciation potential.
Is TFX a buy, sell, or hold?
TFX has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $144.67 implies 11.5% upside from current levels.
Is TFX stock overvalued or undervalued?
With a forward P/E of 19.3553x, TFX trades at a relatively low valuation. The consensus target of $144.67 implies 11.5% appreciation, suggesting meaningful undervaluation.
How high can TFX stock go?
The most bullish Wall Street analyst has a price target of $160 for TFX, while the most conservative target is $116. The consensus of $144.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover TFX stock?
TFX is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the TFX stock forecast?
The 12-month TFX stock forecast based on 29 Wall Street analysts shows a consensus price target of $144.67, with estimates ranging from $116 (bear case) to $160 (bull case). The median consensus rating is "Buy".
What is TFX's forward P/E ratio?
TFX trades at a forward P/E ratio of 19.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy TFX stock?
Wall Street analysts are optimistic on TFX, with a "Buy" consensus rating and $144.67 price target (11.5% upside). 16 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do TFX price targets vary so much?
TFX analyst price targets range from $116 to $160, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $144.67 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare